{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:14:33Z","timestamp":1789704873646,"version":"4.0.1"},"reference-count":142,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Veterinary Sciences"],"abstract":"<jats:p>Canine hemangiosarcoma (HSA) is a relatively common neoplasia, occurring mainly in the skin, spleen, liver and right atrium. Despite the numerous studies investigating the treatment of canine HSA, no significant improvement in survival has been achieved in the last 20 years. Advancements in genetic and molecular profiling presented molecular similarities between canine HSA and human angiosarcoma. It could therefore serve as a valuable model for investigating new and more effective treatments in people and dogs. The most common genetic abnormalities in canine HSA have been found in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) and neuroblastoma RAS viral oncogene homolog (NRAS) pathways. Mutations are also found in tumor protein p53 (TP53), phosphatase and tensin homolog (PTEN) and cyclin dependent kinase inhibitor 2A (CDKN2A). Known abnormal protein expression could be exploited to trial new target treatments that could be beneficial for both canine and human patients. Despite the high expression of vascular endothelial growth factor (VEGF) and its receptor (VEGFR), no correlation with overall survival time has ever been found. In this review, we explore the most recent developments in molecular profiling in canine HSA and discuss their possible applications in the prognosis and treatment of this fatal disease.<\/jats:p>","DOI":"10.3390\/vetsci10060387","type":"journal-article","created":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T02:08:15Z","timestamp":1686017295000},"page":"387","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Molecular Profile of Canine Hemangiosarcoma and Potential Novel Therapeutic Targets"],"prefix":"10.3390","volume":"10","author":[{"given":"Pedro Ant\u00f4nio Bronhara","family":"Pimentel","sequence":"first","affiliation":[{"name":"Department of Veterinary Clinic and Surgery, Federal University of Minas Gerais, Belo Horizonte 31270-901, MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3993-038X","authenticated-orcid":false,"given":"Antonio","family":"Giuliano","sequence":"additional","affiliation":[{"name":"Department of Veterinary Clinical Science, Jockey Club College of Veterinary Medicine, City University of Hong Kong, Hong Kong, China"},{"name":"Veterinary Medical Centre, City University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0498-3254","authenticated-orcid":false,"given":"Pawe\u0142 Marek","family":"B\u0119czkowski","sequence":"additional","affiliation":[{"name":"Department of Veterinary Clinical Science, Jockey Club College of Veterinary Medicine, City University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9885-4498","authenticated-orcid":false,"given":"Rodrigo Dos Santos","family":"Horta","sequence":"additional","affiliation":[{"name":"Department of Veterinary Clinic and Surgery, Federal University of Minas Gerais, Belo Horizonte 31270-901, MG, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/(SICI)1096-9098(199603)61:3<170::AID-JSO2>3.0.CO;2-8","article-title":"Prognostic Factors in Angiosarcoma: A Multivariate Analysis of 55 Cases","volume":"61","author":"Naka","year":"1996","journal-title":"J. Surg. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pdpdt.2019.05.026","article-title":"Photodynamic Therapy for Cutaneous Hemangiosarcoma in Dogs","volume":"27","author":"Rocha","year":"2019","journal-title":"Photodiagnosis Photodyn. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"105074","DOI":"10.1016\/j.prevetmed.2020.105074","article-title":"Evaluation of Intrinsic and Extrinsic Risk Factors for Dog Visceral Hemangiosarcoma: A Retrospective Case-Control Study Register-Based in Lazio Region, Italy","volume":"181","author":"Carnio","year":"2020","journal-title":"Prev. Vet. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Baretta, L.T., De Oliveira Dhein, J., Lupion, C.G., Figueiredo, C.D., and Gerardi, D.G. (2021). Occurrence of Cutaneous Neoplasia in Dogs with Actinic Dermatitis in a Veterinary Medical Teaching Hospital\u2014UFRGS, Brazil. Acta Sci. Vet., 49.","DOI":"10.22456\/1679-9216.108639"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1939-1676.1994.tb03248.x","article-title":"Cutaneous Hemangiosarcoma in 25 Dogs: A Retrospective Study","volume":"8","author":"Ward","year":"1994","journal-title":"J. Vet. Intern. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1292\/jvms.13-0064","article-title":"Epidemiological, Clinical and Pathological Features of Primary Cardiac Hemangiosarcoma in Dogs: A Review of 51 Cases","volume":"75","author":"Yamamoto","year":"2013","journal-title":"J. Vet. Med. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2460\/javma.247.4.393","article-title":"Survival Time of Dogs with Splenic Hemangiosarcoma Treated by Splenectomy with or without Adjuvant Chemotherapy: 208 Cases (2001\u20132012)","volume":"247","author":"Wendelburg","year":"2015","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/vsu.13470","article-title":"Outcomes of 43 Small Breed Dogs Treated for Splenic Hemangiosarcoma","volume":"49","author":"Story","year":"2020","journal-title":"Vet. Surg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/jvim.15456","article-title":"Prevalence, Distribution, and Clinical Characteristics of Hemangiosarcoma-Associated Skeletal Muscle Metastases in 61 Dogs: A Whole Body Computed Tomographic Study","volume":"33","author":"Carloni","year":"2019","journal-title":"J. Vet. Intern. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/vsu.12963","article-title":"Anatomic Site and Etiology of Hemorrhage in Small versus Large Dogs with Spontaneous Hemoperitoneum","volume":"47","author":"Fleming","year":"2018","journal-title":"Vet. Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"736329","DOI":"10.3389\/fvets.2021.736329","article-title":"Outcomes and Blood Product Use in 89 Surgically Managed and 79 Medically Managed Cases of Acute Spontaneous Hemoperitoneum in the Dog","volume":"8","author":"Wright","year":"2021","journal-title":"Front. Vet. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.2460\/javma.231.10.1550","article-title":"Paul Woods Epirubicin in the Adjuvant Treatment of Splenic Hemangiosarcoma in Dogs: 59 Cases (1997\u20132004)","volume":"231","author":"Kim","year":"2007","journal-title":"JAVMA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"304","DOI":"10.5326\/JAAHA-MS-6540","article-title":"Adjuvant Doxorubicin with or without Metronomic Cyclophosphamide for Canine Splenic Hemangiosarcoma","volume":"53","author":"Matsuyama","year":"2017","journal-title":"J. Am. Anim. Hosp. Assoc."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"630","DOI":"10.2460\/javma.258.6.630","article-title":"Retrospective Evaluation of Thrombocytopenia and Tumor Stage as Prognostic Indicators in Dogs with Splenic Hemangiosarcoma","volume":"258","author":"Masyr","year":"2021","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.exphem.2006.04.013","article-title":"Canine Hemangiosarcoma Originates from Hematopoietic Precursors with Potential for Endothelial Differentiation","volume":"34","author":"Helm","year":"2006","journal-title":"Exp. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3390\/vetsci2040388","article-title":"Pathobiology of Hemangiosarcoma in Dogs: Research Advances and Future Perspectives","volume":"2","author":"Kim","year":"2015","journal-title":"Vet. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1590\/S0102-09352013000200003","article-title":"Clinical and Pathological Aspects of Multicentric Hemangiosarcoma in a Pinscher Dog","volume":"65","author":"Martins","year":"2013","journal-title":"Arq. Bras. Med. Vet. Zootec."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.ajpath.2013.12.025","article-title":"Identification of Three Molecular and Functional Subtypes in Canine Hemangiosarcoma through Gene Expression Profiling and Progenitor Cell Characterization","volume":"184","author":"Gorden","year":"2014","journal-title":"Am. J. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/vco.12165","article-title":"Interactions between CXCR4 and CXCL12 Promote Cell Migration and Invasion of Canine Hemangiosarcoma","volume":"15","author":"Im","year":"2017","journal-title":"Vet. Comp. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.yexcr.2014.02.020","article-title":"Interleukin-8 Promotes Canine Hemangiosarcoma Growth by Regulating the Tumor Microenvironment","volume":"323","author":"Kim","year":"2014","journal-title":"Exp. Cell. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1177\/0300985819868732","article-title":"Understanding the Efficiency of Splenic Hemangiosarcoma Diagnosis Using Monte Carlo Simulations","volume":"56","author":"Herman","year":"2019","journal-title":"Vet. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Tecilla, M., Gambini, M., Forlani, A., Caniatti, M., Ghisleni, G., and Roccabianca, P. (2019). Evaluation of Cytological Diagnostic Accuracy for Canine Splenic Neoplasms: An Investigation in 78 Cases Using STARD Guidelines. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0224945"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Flory, A., Kruglyak, K.M., Tynan, J.A., McLennan, L.M., Rafalko, J.M., Fiaux, P.C., Hernandez, G.E., Marass, F., Nakashe, P., and Ruiz-Perez, C.A. (2022). Clinical Validation of a Next-Generation Sequencing-Based Multi-Cancer Early Detection \u201cLiquid Biopsy\u201d Blood Test in over 1000 Dogs Using an Independent Testing Set: The CANcer Detection in Dogs (CANDiD) Study. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0266623"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Wilson-Robles, H.M., Bygott, T., Kelly, T.K., Miller, T.M., Miller, P., Matsushita, M., Terrell, J., Bougoussa, M., and Butera, T. (2022). Evaluation of Plasma Nucleosome Concentrations in Dogs with a Variety of Common Cancers and in Healthy Dogs. BMC Vet. Res., 18.","DOI":"10.1186\/s12917-022-03429-8"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"188","DOI":"10.12968\/coan.2017.22.4.188","article-title":"Solar (Actinic) Dermatoses in the Dog and Cat","volume":"22","author":"Scarff","year":"2017","journal-title":"Companion Anim."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jcpa.2018.10.181","article-title":"Canine Cutaneous Haemangiosarcoma: Biomarkers and Survival","volume":"166","author":"Sehaber","year":"2019","journal-title":"J. Comp. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2460\/javma.251.5.559","article-title":"Evaluation of Clinical and Histologic Factors Associated with Survival Time in Dogs with Stage II Splenic Hemangiosarcoma Treated by Splenectomy","volume":"251","author":"Moore","year":"2017","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1476-5829.2012.00335.x","article-title":"In Vitro Effects of the Tyrosine Kinase Inhibitor, Masitinib Mesylate, on Canine Hemangiosarcoma Cell Lines","volume":"10","author":"Lyles","year":"2012","journal-title":"Vet. Comp. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Gardner, H.L., London, C.A., Portela, R.A., Nguyen, S., Rosenberg, M.P., Klein, M.K., Clifford, C., Thamm, D.H., Vail, D.M., and Bergman, P. (2015). Maintenance Therapy with Toceranib Following Doxorubicin-Based Chemotherapy for Canine Splenic Hemangiosarcoma. BMC Vet. Res., 11.","DOI":"10.1186\/s12917-015-0446-1"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/gerona\/glx182","article-title":"Understanding How Dogs Age: Longitudinal Analysis of Markers of Inflammation, Immune Function, and Oxidative Stress","volume":"73","author":"Alexander","year":"2018","journal-title":"J. Gerontol. Ser. A Biol. Sci. Med. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.21873\/invivo.11429","article-title":"Adjuvant Thalidomide and Metronomic Chemotherapy for the Treatment of Canine Malignant Mammary Gland Neoplasms","volume":"32","author":"Lavalle","year":"2018","journal-title":"In Vivo (Brooklyn)"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/vco.12548","article-title":"Retrospective Comparison of First-Line Adjuvant Anthracycline vs Metronomic-Based Chemotherapy Protocols in the Treatment of Stage I and II Canine Splenic Haemangiosarcoma","volume":"18","author":"Treggiari","year":"2020","journal-title":"Vet. Comp. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/vco.12139","article-title":"Comparison of Doxorubicin\u2013Cyclophosphamide with Doxorubicin\u2013Dacarbazine for the Adjuvant Treatment of Canine Hemangiosarcoma","volume":"15","author":"Finotello","year":"2017","journal-title":"Vet. Comp. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Bray, J.P., and Munday, J.S. (2020). Thalidomide Reduces Vascular Endothelial Growth Factor Immunostaining in Canine Splenic Hemangiosarcoma. Vet. Sci., 7.","DOI":"10.3390\/vetsci7020067"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Musser, M.L., Coto, G.M., Lingnan, Y., Mochel, P., and Johannes, C.M. (2022). Pilot Safety Evaluation of Doxorubicin Chemotherapy Combined with Non-Specific Immunotherapy (Immunocidin\u00ae) for Canine Splenic Hemangiosarcoma. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0279594"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Lucroy, M.D., Clauson, R.M., Suckow, M.A., El-Tayyeb, F., and Kalinauskas, A. (2020). Evaluation of an Autologous Cancer Vaccine for the Treatment of Metastatic Canine Hemangiosarcoma: A Preliminary Study. BMC Vet. Res., 16.","DOI":"10.1186\/s12917-020-02675-y"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41417-019-0080-3","article-title":"Dendritic Cell Vaccination plus Low-Dose Doxorubicin for the Treatment of Spontaneous Canine Hemangiosarcoma","volume":"26","author":"Konduri","year":"2019","journal-title":"Cancer Gene Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1111\/jvim.16212","article-title":"Adjuvant Carboplatin for Treatment of Splenic Hemangiosarcoma in Dogs: Retrospective Evaluation of 18 Cases (2011-2016) and Comparison with Doxorubicin-Based Chemotherapy","volume":"35","author":"Faulhaber","year":"2021","journal-title":"J. Vet. Intern. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/vco.12823","article-title":"Evaluation of the Anti-Tumour Activity of Coriolus Versicolor Polysaccharopeptide (I\u2019m-Yunity) Alone or in Combination with Doxorubicin for Canine Splenic Hemangiosarcoma","volume":"20","author":"Gedney","year":"2022","journal-title":"Vet. Comp. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Wong, S., Ehrhart, E.J., Stewart, S., Zismann, V., Cawley, J., Halperin, R., Briones, N., Richter, K., Sivaprakasam, K., and Perdigones, N. (2022). Genomic Landscapes of Canine Splenic Angiosarcoma (Hemangiosarcoma) Contain Extensive Heterogeneity within and between Patients. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0264986"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4670","DOI":"10.1038\/s41467-021-24836-9","article-title":"Canine Tumor Mutational Burden Is Correlated with TP53 Mutation across Tumor Types and Breeds","volume":"12","author":"Alsaihati","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41698-023-00346-3","article-title":"Analyses of Canine Cancer Mutations and Treatment Outcomes Using Real-World Clinico-Genomics Data of 2119 Dogs","volume":"7","author":"Wu","year":"2023","journal-title":"NPJ Precis. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Wang, G., Wu, M., Durham, A.C., Radaelli, E., Mason, N.J., Xu, X.W., and Roth, D.B. (2020). Molecular Subtypes in Canine Hemangiosarcoma Reveal Similarities with Human Angiosarcoma. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0229728"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1541-7786.MCR-20-0937","article-title":"Genomically Complex Human Angiosarcoma and Canine Hemangiosarcoma Establish Convergent Angiogenic Transcriptional Programs Driven by Novel Gene Fusions","volume":"19","author":"Kim","year":"2021","journal-title":"Mol. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.semcancer.2020.07.015","article-title":"Histone Modifications in Epigenetic Regulation of Cancer: Perspectives and Achieved Progress","volume":"83","author":"Neganova","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/vco.12840","article-title":"Manipulating Histone Acetylation Leads to Antitumor Effects in Hemangiosarcoma Cells","volume":"20","author":"Suzuki","year":"2022","journal-title":"Vet. Comp. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10577-014-9406-z","article-title":"Genomic Profiling Reveals Extensive Heterogeneity in Somatic DNA Copy Number Aberrations of Canine Hemangiosarcoma","volume":"22","author":"Thomas","year":"2014","journal-title":"Chromosom. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11523-013-0299-0","article-title":"Low Level of Baseline Circulating VEGF-A Is Associated with Better Outcome in Patients with Vascular Sarcomas Receiving Sorafenib: An Ancillary Study from a Phase II Trial","volume":"9","author":"Penel","year":"2014","journal-title":"Target Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e26779","DOI":"10.1097\/MD.0000000000026779","article-title":"Aberrant PTEN, PIK3CA, PMAPK, and TP53 Expression in Human Scalp and Face Angiosarcoma","volume":"100","author":"Wan","year":"2021","journal-title":"Medicine"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Conciatori, F., Bazzichetto, C., Falcone, I., Ciuffreda, L., Ferretti, G., Vari, S., Ferraresi, V., Cognetti, F., and Milella, M. (2020). Pten Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155337"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Papa, A., and Pandolfi, P.P. (2019). The PTEN\u2013PI3K Axis in Cancer. Biomolecules, 9.","DOI":"10.20944\/preprints201904.0127.v1"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Tamburini, B.A., Trapp, S., Phang, T.L., Schappa, J.T., Hunter, L.E., and Modiano, J.F. (2009). Gene Expression Profiles of Sporadic Canine Hemangiosarcoma Are Uniquely Associated with Breed. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0005549"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Wang, G., Wu, M., Maloneyhuss, M.A., Wojcik, J., Durham, A.C., Mason, N.J., and Roth, D.B. (2017). Actionable Mutations in Canine Hemangiosarcoma. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0188667"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.5326\/JAAHA-MS-6059","article-title":"Association between Macroscopic Appearance of Liver Lesions and Liver Histology in Dogs with Splenic Hemangiosarcoma: 79 Cases (2004\u20132009)","volume":"50","author":"Clendaniel","year":"2014","journal-title":"J. Am. Anim. Hosp. Assoc."},{"key":"ref_55","first-page":"967","article-title":"Canine Visceral Hemangiosarcoma Treated with Surgery Alone or Surgery and Doxorubicin: 37 Cases (2005\u20132014)","volume":"59","author":"Batschinski","year":"2018","journal-title":"Can. Vet. J."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Iglesias, M.J., Cuevas-Higuera, J.L., Bastida-S\u00e1enz, A., De Garnica-Garc\u00eda, M.G., Polledo, L., Perero, P., Gonz\u00e1lez-Fern\u00e1ndez, J., Fern\u00e1ndez-Mart\u00ednez, B., and P\u00e9rez-Mart\u00ednez, C. (2020). Immunohistochemical Detection of P53 and Pp53 Ser392in Canine Hemangiomas and Hemangiosarcomas Located in the Skin. BMC Vet. Res., 16.","DOI":"10.1186\/s12917-020-02457-6"},{"key":"ref_57","first-page":"499","article-title":"Neutering Is Associated with Developing Hemangiosarcoma in Dogs in the Veterinary Medical Database: An Age and Time-Period Matched Case-Control Study (1964\u20132003)","volume":"61","author":"Robinson","year":"2020","journal-title":"Can. Vet. J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"220","DOI":"10.5326\/JAAHA-MS-6346","article-title":"Occurrence and Clinicopathologic Features of Splenic Neoplasia Based on Body Weight: 325 Dogs (2003\u20132013)","volume":"52","author":"Sherwood","year":"2016","journal-title":"J. Am. Anim. Hosp. Assoc."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Torres de la Riva, G., Hart, B.L., Farver, T.B., Oberbauer, A.M., Messam, L.L.M.V., Willits, N., and Hart, L.A. (2013). Neutering Dogs: Effects on Joint Disorders and Cancers in Golden Retrievers. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0055937"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/vms3.34","article-title":"Neutering of German Shepherd Dogs: Associated Joint Disorders, Cancers and Urinary Incontinence","volume":"2","author":"Hart","year":"2016","journal-title":"Vet. Med. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3892\/or.2022.8295","article-title":"In Vitro Anticancer Effects of Alpelisib against PIK3CA-mutated Canine Hemangiosarcoma Cell Lines","volume":"47","author":"Maeda","year":"2022","journal-title":"Oncol. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Igase, M., Fujiki, N., Shibutani, S., Sakai, H., Noguchi, S., Nemoto, Y., and Mizuno, T. (2020). Tenovin-6 Induces the SIRT-Independent Cell Growth Suppression and Blocks Autophagy Flux in Canine Hemangiosarcoma Cell Lines. Exp. Cell. Res., 388.","DOI":"10.1016\/j.yexcr.2019.111810"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1158\/1541-7786.MCR-19-0221","article-title":"Comparative Genomics Reveals Shared Mutational Landscape in Canine Hemangiosarcoma and Human Angiosarcoma","volume":"17","author":"Megquier","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1354\/vp.42-5-618","article-title":"Mutations of Phosphatase and Tensin Homolog Deleted from Chromosome 10 in Canine Hemangiosarcoma","volume":"42","author":"Dickerson","year":"2005","journal-title":"Vet. Pathol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"dmm049044","DOI":"10.1242\/dmm.049044","article-title":"Comparison of the Oncogenomic Landscape of Canine and Feline Hemangiosarcoma Shows Novel Parallels with Human Angiosarcoma","volume":"14","author":"Wong","year":"2021","journal-title":"DMM Dis. Models Mechan."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Hasbullah, H.H., and Musa, M. (2021). Gene Therapy Targeting P53 and Kras for Colorectal Cancer Treatment: A Myth or the Way Forward?. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111941"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1089\/hum.2017.218","article-title":"The First Approved Gene Therapy Product for Cancer Ad-P53 (Gendicine): 12 Years in the Clinic","volume":"29","author":"Zhang","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/vco.12829","article-title":"Long-term Survival of Dogs with Stage 4 Oral Malignant Melanoma Treated with Anti-canine Therapeutic Antibody: A Follow-up Case Report","volume":"20","author":"Igase","year":"2022","journal-title":"Vet. Comp. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Pantelyushin, S., Ranninger, E., Guerrera, D., Hutter, G., Maake, C., Markkanen, E., Bettschart-Wolfensberger, R., Bley, C.R., L\u00e4ubli, H., and Vom Berg, J. (2021). Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs. Cancers, 13.","DOI":"10.3390\/cancers13040785"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","article-title":"PD-1 and PD-L1 in Cancer Immunotherapy: Clinical Implications and Future Considerations","volume":"15","author":"Jiang","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2460\/javma.245.4.401","article-title":"Efficacy of Systemic Adjuvant Therapies Administered to Dogs after Excision of Oral Malignant Melanomas: 151 Cases (2001\u20132012)","volume":"245","author":"Boston","year":"2014","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"888483","DOI":"10.3389\/fvets.2022.888483","article-title":"Pharmacokinetic Exposures Associated With Oral Administration of Sorafenib in Dogs With Spontaneous Tumors","volume":"9","author":"Cawley","year":"2022","journal-title":"Front. Vet. Sci."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Marconato, L., Sabattini, S., Marisi, G., Rossi, F., Leone, V.F., and Casadei-Gardini, A. (2020). Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs. Cancers, 12.","DOI":"10.3390\/cancers12051272"},{"key":"ref_74","first-page":"97","article-title":"Tolerability of Oral Sorafenib in Pet Dogs with a Diagnosis of Cancer","volume":"8","author":"Foskett","year":"2017","journal-title":"Vet. Med. Res. Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3892\/or.2022.8272","article-title":"Antitumor Activity of the Dual PI3K\/MTOR Inhibitor Gedatolisib and the Involvement of ABCB1 in Gedatolisib Resistance in Canine Tumor Cells","volume":"47","author":"Murase","year":"2022","journal-title":"Oncol. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ctro.2020.11.003","article-title":"Dacomitinib and Gedatolisib in Combination with Fractionated Radiation in Head and Neck Cancer","volume":"26","author":"Wilson","year":"2021","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12935-021-01800-7","article-title":"ABCB1 and ABCG2 Restricts the Efficacy of Gedatolisib (PF-05212384), a PI3K Inhibitor in Colorectal Cancer Cells","volume":"21","author":"Liu","year":"2021","journal-title":"Cancer Cell Int."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s40265-019-01161-6","article-title":"Alpelisib: First Global Approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The Frequency of Ras Mutations in Cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.exphem.2008.09.005","article-title":"RAS, FLT3, and C-KIT Mutations in Immunophenotyped Canine Leukemias","volume":"37","author":"Usher","year":"2009","journal-title":"Exp. Hematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3748\/wjg.v21.i5.1488","article-title":"MiR-21\/RASA1 Axis Affects Malignancy of Colon Cancer Cells via RAS Pathways","volume":"21","author":"Gong","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1111\/vco.12275","article-title":"Sequence Analysis of RAS and RAF Mutation Hot Spots in Canine Carcinoma","volume":"15","author":"Mochizuki","year":"2017","journal-title":"Vet. Comp. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1136\/vr.153.3.87","article-title":"K-Ras Mutations in Canine Pancreatic Cancers","volume":"153","author":"Mayr","year":"2003","journal-title":"Vet. Rec."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/carcin\/19.6.959","article-title":"Rapid Detection of K-Ras Gene Mutations in Canine Lung Cancer Using Single-Strand Conformational Polymorphism Analysis","volume":"19","author":"Griffey","year":"1998","journal-title":"Carcinogenesis"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Degirmenci, U., Wang, M., and Hu, J. (2020). Targeting Aberrant RAS\/RAF\/MEK\/ERK Signaling for Cancer Therapy. Cells, 9.","DOI":"10.3390\/cells9010198"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.3892\/or.2020.7807","article-title":"Role of RASA1 in Cancer: A Review and Update (Review)","volume":"44","author":"Zhang","year":"2020","journal-title":"Oncol. Rep."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"12043","DOI":"10.18632\/aging.102539","article-title":"CircAHNAK1 Inhibits Proliferation and Metastasis of Triple-Negative Breast Cancer by Modulating MiR-421 and RASA1","volume":"11","author":"Xiao","year":"2019","journal-title":"Aging"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Pottier, C., Fresnais, M., Gilon, M., J\u00e9rusalem, G., Longuesp\u00e9e, R., and Sounni, N.E. (2020). Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy. Cancers, 12.","DOI":"10.3390\/cancers12030731"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.canlet.2015.11.034","article-title":"MicroRNA-122 Confers Sorafenib Resistance to Hepatocellular Carcinoma Cells by Targeting IGF-1R to Regulate RAS\/RAF\/ERK Signaling Pathways","volume":"371","author":"Xu","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1158\/1535-7163.MCT-12-0893","article-title":"Pharmacologic Inhibition of MEK Signaling Prevents Growth of Canine Hemangiosarcoma","volume":"12","author":"Andersen","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/1060028016672037","article-title":"Cobimetinib: A Novel MEK Inhibitor for Metastatic Melanoma","volume":"51","author":"Signorelli","year":"2017","journal-title":"Ann. Pharmacother."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"18630","DOI":"10.1038\/s41598-019-54901-9","article-title":"MEK Inhibition Enhances the Response to Tyrosine Kinase Inhibitors in Acute Myeloid Leukemia","volume":"9","author":"Morales","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fonc.2014.00035","article-title":"PIK3CA in Colorectal Cancer","volume":"4","author":"Cathomas","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.semcancer.2019.02.002","article-title":"PIK3CA in Cancer: The Past 30 Years","volume":"59","author":"Arafeh","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Murai, A., Asa, S.A., Kodama, A., Hirata, A., Yanai, T., and Sakai, H. (2012). Constitutive Phosphorylation of the MTORC2\/Akt\/4E-BP1 Pathway in Newly Derived Canine Hemangiosarcoma Cell Lines. BMC Vet. Res., 8.","DOI":"10.1186\/1746-6148-8-128"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Langdon, S.P., Kay, C., Um, I.H., Dodds, M., Muir, M., Sellar, G., Kan, J., Gourley, C., and Harrison, D.J. (2019). Evaluation of the Dual MTOR\/PI3K Inhibitors Gedatolisib (PF-05212384) and PF-04691502 against Ovarian Cancer Xenograft Models. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-55096-9"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Pyuen, A.A., Meuten, T., Rose, B.J., and Thamm, D.H. (2022). In Vitro Effects of PI3K\/MTOR Inhibition in Canine Hemangiosarcoma. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0200634"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"8127","DOI":"10.1158\/0008-5472.CAN-08-0755","article-title":"PIK3CA Cooperates with Other Phosphatidylinositol 3\u2032-Kinase Pathway Mutations to Effect Oncogenic Transformation","volume":"68","author":"Oda","year":"2008","journal-title":"Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Kim, S.H., Seung, B.J., Cho, S.H., Lim, H.Y., Bae, M.K., and Sur, J.H. (2021). Dysregulation of Pi3k\/Akt\/Pten Pathway in Canine Mammary Tumor. Animals, 11.","DOI":"10.3390\/ani11072079"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","article-title":"Attacking the PI3K\/Akt\/MTOR Signaling Pathway for Targeted Therapeutic Treatment in Human Cancer","volume":"85","author":"Yu","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrurol.2018.9","article-title":"Clinical Implications of PTEN Loss in Prostate Cancer","volume":"15","author":"Jamaspishvili","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.semcancer.2019.02.001","article-title":"Mechanisms of PTEN Loss in Cancer: It\u2019s All about Diversity","volume":"59","author":"Tawil","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.rvsc.2007.10.015","article-title":"Expression and Significance of PTEN in Canine Mammary Gland Tumours","volume":"85","author":"Qiu","year":"2008","journal-title":"Res. Vet. Sci."},{"key":"ref_106","unstructured":"(2007). Wyeth Pharmaceuticals. TORISELTMKit (Temsirolimus). (No. 5,362,718), U.S Patent."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of Everolimus in Advanced Renal Cell Carcinoma: A Double-Blind, Randomised, Placebo-Controlled Phase III Trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1007\/s10637-013-0028-7","article-title":"Multicenter Phase II Study of Everolimus in Patients with Metastatic or Recurrent Bone and Soft-Tissue Sarcomas after Failure of Anthracycline and Ifosfamide","volume":"31","author":"Yoo","year":"2013","journal-title":"Invest. New Drugs"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1100602","DOI":"10.3389\/fonc.2023.1100602","article-title":"MTOR Pathway as a Potential Therapeutic Target for Cancer Stem Cells in Canine Mammary Carcinoma","volume":"13","author":"Michishita","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1158\/1078-0432.CCR-21-0315","article-title":"Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs","volume":"27","author":"LeBlanc","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Giuliano, A., Horta, R.S., Vieira, R.A.M., Hume, K.R., and Dobson, J. (2023). Repurposing Drugs in Small Animal Oncology Repurposing Drugs in Small Animal Oncology. Animals, 13.","DOI":"10.3390\/ani13010139"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1186\/s12935-021-02396-8","article-title":"p53 Signaling in Cancer Progression and Therapy","volume":"21","author":"Marei","year":"2021","journal-title":"Cancer Cell Int."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"eaan4672","DOI":"10.1126\/science.aan4672","article-title":"Gene Therapy Comes of Age","volume":"359","author":"Dunbar","year":"2018","journal-title":"Science"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41577-022-00751-y","article-title":"DNA Damage and Repair in Age-Related Inflammation","volume":"23","author":"Zhao","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/bjd.14485","article-title":"CDKN2A Mutations with P14 Loss Predisposing to Multiple Nerve Sheath Tumours, Melanoma, Dysplastic Naevi and Internal Malignancies: A Case Series and Review of the Literature","volume":"175","author":"Sargen","year":"2016","journal-title":"British J. Dermatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ebiom.2016.04.017","article-title":"Implications of Genetic and Epigenetic Alterations of CDKN2A (P16INK4a) in Cancer","volume":"8","author":"Zhao","year":"2016","journal-title":"EBioMedicine"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Cicenas, J., Kvederaviciute, K., Meskinyte, I., Meskinyte-Kausiliene, E., and Skeberdyte, A. (2017). KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer. Cancers, 9.","DOI":"10.3390\/cancers9050042"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.humpath.2020.06.003","article-title":"A Genomic Survey of Sarcomas on Sun-Exposed Skin Reveals Distinctive Candidate Drivers and Potentially Targetable Mutations","volume":"102","author":"Miller","year":"2020","journal-title":"Hum. Pathol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"19753","DOI":"10.18632\/oncotarget.24831","article-title":"Mouse Genetic Background Influences Whether Hras G12V Expression plus Cdkn2a Knockdown Causes Angiosarcoma or Undifferentiated Pleomorphic Sarcoma","volume":"9","author":"Brandt","year":"2018","journal-title":"Oncotarget"},{"key":"ref_120","first-page":"455","article-title":"Vascular Endothelial Growth Factor (VEGF)-Key Factor in Normal and Pathological Angiogenesis","volume":"59","author":"Melincovici","year":"2018","journal-title":"Rom. J. Morphol. Embryol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12935-020-01719-5","article-title":"The Role of Hypoxia in the Tumor Microenvironment and Development of Cancer Stem Cell: A Novel Approach to Developing Treatment","volume":"21","author":"Nejad","year":"2021","journal-title":"Cancer Cell Int."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41419-018-0790-8","article-title":"FOXP3 Inhibits Angiogenesis by Downregulating VEGF in Breast Cancer","volume":"9","author":"Li","year":"2018","journal-title":"Cell. Death Dis."},{"key":"ref_123","first-page":"190","article-title":"Anti-Angiogenic Therapies for the Treatment of Angiosarcoma: A Clinical Update","volume":"10","author":"Young","year":"2017","journal-title":"Mag. Eur. Med. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.semcancer.2017.12.002","article-title":"Predictive Markers of Anti-VEGF and Emerging Role of Angiogenesis Inhibitors as Immunotherapeutics","volume":"52","author":"Hegde","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jdermsci.2019.01.005","article-title":"Hypoxia Accelerates the Progression of Angiosarcoma through the Regulation of Angiosarcoma Cells and Tumor Microenvironment","volume":"93","author":"Kajihara","year":"2019","journal-title":"J. Dermatol. Sci."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.3892\/or.2015.3856","article-title":"Prognostic Value of Vascular Endothelial Growth Factor and Hypoxia-Inducible Factor 1\u03b1 in Canine Malignant Mammary Tumors","volume":"33","author":"Moschetta","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12943-020-01288-1","article-title":"Mechanisms of Vasculogenic Mimicry in Hypoxic Tumor Microenvironments","volume":"20","author":"Wei","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1089\/ars.2013.5378","article-title":"The Clinical Importance of Assessing Tumor Hypoxia: Relationship of Tumor Hypoxia to Prognosis and Therapeutic Opportunities","volume":"21","author":"Walsh","year":"2014","journal-title":"Antioxid. Redox Signal."},{"key":"ref_129","first-page":"1502","article-title":"Loss of Autocrine Endothelial-Derived VEGF Significantly Reduces Hemangiosarcoma Development in Conditional P53-Deficient Mice","volume":"13","author":"Ghahremani","year":"2014","journal-title":"Cell Cycle"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1292\/jvms.15-0625","article-title":"Immunohistochemical Detection of a Potential Molecular Therapeutic Target for Canine Hemangiosarcoma","volume":"78","author":"Adachi","year":"2016","journal-title":"J. Vet. Med. Sci."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Lebellec, L., Bertucci, F., Tresch-Bruneel, E., Ray-Coquard, I., Le Cesne, A., Bompas, E., Blay, J.Y., Italiano, A., Mir, O., and Ryckewaert, T. (2018). Prognostic and Predictive Factors for Angiosarcoma Patients Receiving Paclitaxel Once Weekly plus or Minus Bevacizumab: An Ancillary Study Derived from a Randomized Clinical Trial. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4828-1"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4236\/ojvm.2012.24030","article-title":"Juliana Alvares Duarte Bonini Campos; Daniel Soares Sanches; Maria L\u00facia Zaidan Dagli; Julia Maria Matera Immunohistochemical Evaluation of Vascular Endothelial Growth Factor (VEGF) in Splenic Hemangiomas and Hemangiosarcomas in Dogs","volume":"2","author":"Campos","year":"2012","journal-title":"Open J. Vet. Med."},{"key":"ref_133","first-page":"2303","article-title":"Angiosarcoma: A Review of Diagnosis and Current Treatment","volume":"9","author":"Cao","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jss.2020.07.026","article-title":"Multidisciplinary Management of Angiosarcoma\u2014A Review","volume":"257","author":"Sturm","year":"2021","journal-title":"J. Surg. Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/jsap.12613","article-title":"Use of Oncept Melanoma Vaccine in 69 Canine Oral Malignant Melanomas in the UK","volume":"58","author":"Verganti","year":"2017","journal-title":"J. Small Anim. Pract."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"012012","DOI":"10.1088\/1742-6596\/1953\/1\/012012","article-title":"Safety and Efficacy of OncoTherad Nano-Immunotherapy in Patients with Non-Muscle Invasive Bladder Cancer","volume":"1953","author":"Alonso","year":"2021","journal-title":"J. Phys. Conf. Ser."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"012022","DOI":"10.1088\/1742-6596\/1323\/1\/012022","article-title":"New Therapeutic Perspective for Bladder Cancer in Dogs: Toxicological and Clinical Effects of OncoTherad Nanostructured Immunotherapy","volume":"1323","author":"Tizziani","year":"2019","journal-title":"J. Phys. Conf. Ser."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"012018","DOI":"10.1088\/1742-6596\/1323\/1\/012018","article-title":"OncoTherad: A New Nanobiological Response Modifier, Its Toxicological and Anticancer Activities","volume":"1323","author":"Dias","year":"2019","journal-title":"J. Phys. Conf. Ser."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"100296","DOI":"10.1016\/j.ctarc.2020.100296","article-title":"Role of Immunotherapy in Bladder Cancer","volume":"26","author":"Rhea","year":"2021","journal-title":"Cancer Treat Res. Commun."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Gulay, K.C.M., Aoshima, K., Maekawa, N., Suzuki, T., Konnai, S., Kobayashi, A., and Kimura, T. (2022). Hemangiosarcoma Cells Induce M2 Polarization and PD-L1 Expression in Macrophages. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-06203-w"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Maekawa, N., Konnai, S., Okagawa, T., Nishimori, A., Ikebuchi, R., Izumi, Y., Takagi, S., Kagawa, Y., Nakajima, C., and Suzuki, Y. (2016). Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0157176"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Reis, I.B., Tibo, L.H.S., de Souza, B.R., Dur\u00e1n, N., and F\u00e1varo, W.J. (2022). OncoTherad\u00ae Is an Immunomodulator of Biological Response That Downregulate RANK\/RANKL Signaling Pathway and PD-1\/PD-L1 Immune Checkpoint in Non-Muscle Invasive Bladder Cancer. J. Cancer Res. Clin. Oncol., 20\u201330.","DOI":"10.1007\/s00432-022-04449-5"}],"container-title":["Veterinary Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2306-7381\/10\/6\/387\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:48:32Z","timestamp":1760125712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2306-7381\/10\/6\/387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,5]]},"references-count":142,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["vetsci10060387"],"URL":"https:\/\/doi.org\/10.3390\/vetsci10060387","relation":{},"ISSN":["2306-7381"],"issn-type":[{"value":"2306-7381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,5]]}}}